Adebrelimab clinical trials
Also written SHR-1316 and HTI-1088.
How each study uses adebrelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the adebrelimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
204 studies that test it; most in 2024 (77)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 19 |
| 2024 | 77 |
| 2025 | 45 |
| 2026 | 46 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 44 · Other 161
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (18) · Fudan University (13) · Tianjin Medical University Cancer Institute and Hospital (11) · Jiangsu HengRui Medicine Co., Ltd. (9) · Shanghai Hengrui Pharmaceutical Co., Ltd. (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Sun Yat-sen University (6) · Peking University Cancer Hospital & Institute (6)
Often tested with
Tested in the same studies.
Apatinib (29) · Trastuzumab rezetecan (18) · Paclitaxel (8) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (7) · KRAS G12D Inhibitor HRS-4642 (7) · Antineoplastic Agents (7) · Notiretatug rezetecan (7) · SHR-1701 (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 58, 1 in phase 3
Studies that test adebrelimab, phase 3 first.
- Aug 2027The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung CancerPhase 3 · Shanghai Pulmonary Hospital, Shanghai, China
- Nov 2026Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaPhase 2 · Nanfang Hospital, Southern Medical University
- Nov 2026Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular CarcinomaPhase 2 · The First Affiliated Hospital of Xiamen University
- Nov 2026Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer PatientsEarly Phase 1 · Nanjing Tianyinshan Hospital
- Dec 2026MRNA Neoantigen Vaccine in Non-Small Cell Lung CancerEarly Phase 1 · Guangdong Provincial People's Hospital
- Dec 2026A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourPhase 2 · Shandong Suncadia Medicine Co., Ltd.
- Dec 2026Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaPhase 2 · Henan Cancer Hospital
- Dec 2026Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionPhase 2 · Qilu Hospital of Shandong University
- Dec 2026Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLCPhase 2 · Zhangzhou Municipal Hospital
Studies
Open first, then newest update. How each study uses adebrelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 205
- Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)RecruitingPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06879145Written as Adebrelimab
- PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)RecruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT07267234Written as Adebrelimab
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07863167Written as adebrelimab + SHR-A2009
- Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Qun ZhaoNCT07924332Written as Adebrelimab Plus chemotherapy
- Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal CancerNot yet recruitingPhase 2Henan Cancer HospitalNCT07905950Written as Adebrelimab
- A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07691762Written as SHR-8068 + Adebrelimab + Bevacizumab
- Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06510660Written as adebrelimab
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerNot yet recruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07900789Written as HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection
- A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLCNot yet recruitingPhase 3West China HospitalNCT07895238Written as Adebrelimab (SHR-1316) + chemotherapy
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07896005Written as Adebrelimab Injection
- An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07806058Written as HRS-7172 + AG + SHR-1316
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as SHR-1316
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT07824882Written as Adebrelimab Injection
- Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCNot yet recruitingPhase 2Ruijin HospitalNCT07890636Written as Adebrelimab
- Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerRecruitingPhase 1Second Xiangya Hospital of Central South UniversityNCT07886047Written as Adebrelimab
- A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLCRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07798947Written as SHR-1316
- Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tongji HospitalNCT07865611Written as Adebrelimab
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as Adebrelimab
- Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNot yet recruitingPhase 2Ming ChenNCT07836543Written as Adebrelimab
- Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerRecruitingPhase 2Jiangmen Central HospitalNCT07583550Written as Adebrelimab
See all 205 studies that test adebrelimab →
Given beside what is tested · 52 — adebrelimab is usual care or a partner of the new treatment
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625Written as Adebrelimab Injection
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)RecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664Written as Adebrelimab
- A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07136142Written as SHR-1316 Injection
- A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07822542Written as Adebrelimab
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002Written as Adebrelimab Injection
- Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.RecruitingPhase 2Fudan UniversityNCT07638852Written as Adebelimab
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Written as Adebrelimab
- Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary GlioblastomaNot yet recruitingPhase 2Wei JiangNCT07789379Written as Adebrelimab
- A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07770113Written as Adebrelimab
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as Adebrelimab
- A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07682272Written as Adebrelimab Injection
- Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal AdenocarcinomaRecruitingPhase 1/2Fudan UniversityNCT06427239Written as Adebrelimab
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474455Written as SHR-1316 Injection
- Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)RecruitingPhase 2Sun Yat-sen UniversityNCT07241793Written as Adebrelimab
- Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCCNot yet recruitingPhase 2Chen ChunyanNCT07554768Written as Adebrelimab
- Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingPhase 2Fudan UniversityNCT07466927Written as SHR-1316
- Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)RecruitingPhase 2Sichuan UniversityNCT06610734Written as Adebrelimab
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma:A Randomized, Non-comparative Phase 2 StudyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07266025Written as Adebrelimab
- Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid TumorsRecruitingPhase 1Xian-Jun YuNCT07348042Written as Adebelimab Injection
- A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid TumorsRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07268040Written as SHR-1316 Injection
Showing 20 of 52.
As the comparator · 3 — what is tested is compared with adebrelimab
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingPhase 2Tan LijieNCT07770672Written as Adebrelimab Plus Chemotherapy
- Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung CancerNot yet recruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07560358Written as adebrelimab,Radiation Therapy,Radiotherapy
- Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical TrialNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06771154Written as Adebelimab
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting4
- PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)Oct 27, 2026NCT07267234
- An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid TumorsOct 26, 2026NCT07806058
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsOct 23, 2026NCT07824882
- A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLCOct 19, 2026NCT07798947
Newly registered7
- Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNov 9, 2026NCT07924332
- Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal CancerOct 30, 2026NCT07905950
- HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic CancerOct 28, 2026NCT07900789
- A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLCOct 26, 2026NCT07895238
- A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerOct 26, 2026NCT07896005
Show 2 moreShow fewer
- Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLCOct 22, 2026NCT07890636
- Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung CancerOct 21, 2026NCT07886047
Codes
What other systems call adebrelimab · ClinicalTrials.gg INT014364
- UNII (FDA) 1XBY50W1OXADEBRELIMABOne source FDA
- NCI Thesaurus C148535AdebrelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1XBY50W1OX | ADEBRELIMAB | One source FDA |
| NCI Thesaurus | C148535 | Adebrelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.